Skip to main content
Article
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet Diabetes & Endocrinology (2021)
  • Matthias von Herrath, Novo Nordisk
  • Stephen C Bain, Swansea University
  • Bruce Bode, Emory University
  • Jesper Ole Clausen, Novo Nordisk
  • Ken Coppieters, Novo Nordisk
  • Leylya Gaysina, Kazan Federal University
  • Janusz Gumprecht, Medical University of Silesia
  • Troels Krarup Hansen, Aarhus University Hospital
  • Chantal Mathieu, Katholieke Universiteit Leuven
  • Cristobal Morales
  • Ofri Mosenzon, Hebrew University of Jerusalem
  • Stine Segel, Novo Nordisk
  • George Tsoukas, McGill University
  • Thomas R Pieber, Medical University of Graz
  • Bernhard Ludvik
  • Rudolf Prager
  • Bernhard Paulweber
  • Christoph F Ebenbichler
  • B Keymeulen
  • C De Block
  • Loren Grossman
  • Robyn Houlden
  • Patrice Perron
  • Thomas Ransom
  • Peter Senior
  • S. John Weisnagel
  • Vincent Woo
  • Richard Dumas
  • David Thompson
  • Tina Vilsbøll
  • Jeppe Gram
  • Claus Bogh Juhl
  • Janne Hukkanen
  • Jorma Lahtela
  • Leo Niskanen
  • Donal O'Shea
  • Timothy O'Brien
  • Seamus Sreenan
  • Julio Wainstein
  • Moshe Phillip
  • Hilla Knobler
  • Francesco Dotta
  • Pier Marco Piatti
  • Trevisan Roberto
  • Agostino Gnasso
  • Hanne Gulseth
  • John Cooper
  • Ewa Pankowska
  • Monika Lukaszewicz
Publication Date
April 1, 2021
DOI
10.1016/S2213-8587(21)00019-X
Citation Information
Matthias von Herrath, Stephen C Bain, Bruce Bode, Jesper Ole Clausen, et al.. "Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet Diabetes & Endocrinology Vol. 9 Iss. 4 (2021) p. 212 - 224
Available at: http://works.bepress.com/samer-nakhle/9/